Story-of-the-week
Booster interval and age updatedThe U.S. Food and Drug
Administration (FDA) and CDC authorizing the use of a Pfizer-BioNTech & Moderna COVID-19 Vaccine to shorten the time
between the completion of a primary series of the 2 vaccines and a booster dose
to at least 5 months after completion of the primary vaccination series for
individuals 12 yea...
TAKE-HOME MESSAGE
Patients who are hospitalized with COVID-19 have
been shown to have a high risk of thromboembolic events post discharge. In
this open-label randomized trial, the authors showed that, in high-risk
patients who are hospitalized for COVID-19, the use of thromboprophylaxis
and rivaroxaban for 35 days after di...
The U.S. Food and Drug
Administration revised the emergency use authorization (EUA) of bamlanivimab
and etesevimab monoclonal antibodies (previously authorized for pediatric
patients 12 years of age and older weighing at least 40 kilograms, or about 88
pounds), to additionally authorize bamlanivimab and etesivimab administered
together for the...
The World Health Organization (WHO)
says early evidence suggests the omicron variant may be spreading faster than
the highly transmissible delta variant but brings with it less severe
coronavirus disease though it’s too early to make firm conclusions. Omicron Now in 57 Countries, Could Have Major Impact on Pandemic, Says
WHO.· New
corona...
Sotrovimab has been approved for patients with mild-to-moderate
COVID-19 who are at high risk of developing severe disease.The Medicines and Healthcare
products Regulatory Agency (MHRA) has approved the monoclonal antibody
treatment Sotrovimab (Xevudy; GSK and Vir Biotechnology) for people with
mild-to-moderate COVID-19 and at least one risk fa...
AZD7442 is a combination of two
long-acting antibodies (LAABs) - Tixagevimab and Cilgavimab - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus.The AstraZeneca drug AZD7442, has
been undergoing final stage clinical trials to assess its safety and efficacy. AstraZeneca’s
antibody treatment has been shown to be highly ef...
Britain authorizes Merck’s Molnupiravir,
the world’s first approval of oral covid-19 treatment pill. The drug is waiting
for FDA review and approval. Britain became the first country in the
world to approve a potentially game-changing Covid-19 antiviral pill jointly
developed by US drugmaker Merck and Ridgeback Biotherapeutics, i...
FDA authorized the emergency use of the Pfizer-BioNTech
COVID-19 Vaccine for the prevention of COVID19 to include
children 5 through 11 years of age.
Key points:
Effectiveness: Immune responses of
children 5 through 11 years of age were comparable to those of individuals
16 through 25 years of age. In addition, t...
Association between COVID-19 and
Myocarditis Using Hospital-Based Administrative Data — United States, March
2020–January 2021
Viral infections are a common
cause of myocarditis, an inflammation of the heart muscle (myocardium) that can
result in hospitalization, heart failure, and sudden death. Emerging data
suggest an association between...
Food and Drug Administration
advisory committee (US FDA) unanimously recommend the third shots to people age
65 and older and those at a high risk of suffering from severe illness if they
get the coronavirus.
Rejected a proposal to distribute
booster/third shots of Pfizer and BioNTech’s Covid-19 vaccine to the General Public. RemoveA...
Having a comprehensive
understanding of the transmission patterns of SARS-CoV-2
is necessary for the successful implementation of these public health
measures.For example, obtaining
information about when individuals with SARS-CoV-2 are most likely to spread
the virus may guide decisions about the duration of contact tracing an...
Patients with asthma were considered to be at elevated risk early in
the COVID-19 pandemic. The study showed that physical
activity was less in patients with asthma. However, the groups had similar
fear, perceived stress, and quality of life. Total physical activity level,
vigorous physical activity level, and walking score of patients wit...
